At GEA we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product life-cycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
Our solution for continuous tableting lines is ConsiGma®, a 6 sigma-inspired manufacturing platform, incorporating different technologies to produce oral solid dosage forms in a continuous, cost-efficient way:
Showing 4 of 6
The ConsiGma® CF20 test rig is a standalone module that allows you to characterize the feeding behavior of your products during the early stages of R&D.
An indispensable part of the ConsiGma 4.0 portfolio, the Conductor 4.0 control system architecture ensures smooth operation and communication between the different elements of a pharmaceutical continuous manufacturing line
A highly integrated solution for continuous linear blending and direct compression, the ConsiGma® DC-LB lines offer all the advantages of continuous manufacturing: supply chain agility, small footprint, controlled blending and compression and improved quality.
Designed to achieve optimal blending results, the ConsiGma® DB modules facilitate the testing of dosing and blending operations and can be integrated with any continuous up- or downstream process.
After reaching its Mission 26 targets two years early, GEA launches Mission 2030 strategy with focus on growth, value and making a positive impact.
As more communities and businesses rely on district heat pump plants and climate-neutral refrigeration technology, ensuring they provide a continuous supply is of vital importance. GEA’s InsightPartner Blu-Red Care management...
Committed to bring Swiss production of wood insulation boards back to life, Lignatherm AG is counting on GEA’s innovative three-stage solution for water treatment to recycle nearly 100% of effluent water from wood fiber manufacture....